Home › Companies › INBX
Inhibrx Biosciences
Market cap $1.10B 14.8M shares (10-Q, Nov 6, 2026) × $74.18 close Nov 17, 2026
Most recent annual filing: 2026-03-19
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- Ozekibart FDA feedback4Q 2026Ozekibart FDA feedback, 4Q 2026, notable
- Ozekibart interim1Q 2027Ozekibart interim, 1Q 2027, notable
- INBRX-106 trial start2027INBRX-106 trial start, 2027, notable
- Ozekibart enrollment done2027Ozekibart enrollment done, 2027, routine
- Ozekibart chondrosarcoma BLA PDUFA dateApr 14, 2027Ozekibart chondrosarcoma BLA PDUFA date, Apr 14, 2027, major
- INBRX-106 interim2H 2027INBRX-106 interim, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (6 active programs)
ozekibart
INBRX-109
ordastobart
INBRX-106 Technology platforms
Capital (as filed)
- Cash
- $199M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$34.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $200M cash, runway late 2027 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Inhibrx Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-03 Speculative buy speculative Inhibrx Biosciences (INBX) — Scientific Deep Dive for INBRX-106, Ozekibart (INBRX-109) and Pipeline Products Two shots on goal with a floor: a first-in-disease PDUFA for ozekibart and a hexavalent OX40 agonist with the first randomized ORR delta and matched pharmacodynamic signal in the class, but sized small given $275M secured debt ahead of equity and an open-label Phase 2 with only 11 responders.
- 2026-09-04 Speculative buy speculative UPDATE: Inhibrx Biosciences (INBX) - The Clock Is Set for Tuesday, 5:00 a.m. PT Thesis unchanged ahead of the September 8 HexAgon PFS readout; the April 2027 chondrosarcoma PDUFA provides a catalyst floor independent of the binary print, and position sizing rather than prediction governs.
- 2026-09-08 Speculative buy speculative UPDATE: Inhibrx Biosciences (INBX) - The Curve Separated. The Stock Fell Anyway. HexAgon delivered the first randomized PFS separation by an OX40 agonist (9.6 vs 4.9 months), validating the valency thesis, but Phase 3 initiation slipped behind an expansion cohort and FDA meeting, pushing the funded window further and leaving no hazard ratio disclosed.
- 2026-11-14 Hold UPDATE: Inhibrx Biosciences (INBX) - The ATM Arrives, and the Floor Gets Inspected Downgraded to Hold because both ozekibart manufacturers received FDA Form 483s ahead of the April 2027 PDUFA with explicit CRL risk, a $150M ATM puts a steady seller under the stock, and the 4L CRC accelerated-approval path appears closed; existing holders should stay at 1–2% through the inspection outcome rather than add.
- 2026-11-18 Hold UPDATE: Inhibrx Biosciences (INBX) - The Free Option Gets a Second Look Ewing sarcoma ORR held at 62.7% as cohort grew to 51 patients and FDA-discussion language returned, adding option value to the pipeline, but unresolved Form 483s and the active ATM mean no new money is warranted; holders at 1–2% of book should stay steady through the inspection outcome.
- Long call · opened Sep 3, 2026 at $122.26 · -39.3% vs XBI -11.6% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The progression-free survival data from the Phase 2 portion of the HexAgon study are expected to become available in the third quarter of 2026.”
matched to INBRX-106 · readout other
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (24)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Sep 4, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseInhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma→ BD updateSummary on the 8-K
- Nov 17, 20268-KCurrent report: other events · EX-99.1→ BD updateThe Ewing sarcoma data that lost its regulatory path in August just came back stronger — 62.7% ORR in 51 evaluable patients, mPFS 6.0 months, no hepatotoxicity signal as n doubled, and language from the CEO suggesting a regulatory filing path is back on the table ahead of tomorrow's CTOS poster.
- Nov 13, 2026S-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- Nov 13, 2026ReleaseInhibrx Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 13, 20268-KCurrent report: results of operations · EX-99.1→ BD updateInhibrx launched a $150M ATM equity facility after the close — the dilution I called inevitable has arrived, at $83 versus the $124 pre-data price. But buried in tonight's 10-Q is a more urgent risk: FDA Form 483 manufacturing observations on ozekibart's drug substance and drug product CMOs, a live threat to the April 14, 2027 PDUFA.
- Nov 13, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 13, 2026ReleaseInhibrx Announces Participation in Upcoming Scientific ConferencesBD extracted 2 program updates from this document → INBX pipeline
- Sep 28, 20268-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 2 program updates from this document → INBX pipeline
- Sep 8, 2026ReleaseInhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study→ BD updateSummary on the 8-K
- Sep 8, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe HexAgon Phase 2 primary endpoint just printed the cleanest OX40 data ever generated in a randomized study — 9.6 months median PFS versus 4.9 months for pembrolizumab alone, with an HPV+ subgroup signal so strong (80% cORR, 90% PFS6, median PFS not reached) that Inhibrx is now pursuing accelerated approval rather than jumping straight to Phase 3.BD extracted 1 program update from this document → INBX pipeline
- Sep 4, 2026ReleaseInhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study→ BD updateInhibrx just set the clock: the HexAgon Phase 2 PFS readout — the binary I called the valuation's entire spine — drops Tuesday, September 8 at 5:00 a.m. PT via live webcast, four trading days away.BD extracted 1 program update from this document → INBX pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Jul 16, 20268-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1
- Jun 15, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Jun 3, 20268-KCurrent report: shareholder vote
- May 14, 20268-KCurrent report: results of operations · EX-99.1
- May 14, 202610-QQuarterly report
- May 11, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 23, 2026DEFA14AProxy soliciting material
- Apr 23, 2026DEF 14AProxy statement
- Apr 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Mar 19, 20268-KCurrent report: results of operations · EX-99.1
- Mar 19, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)